Facile purification and characterization of recombinant human antithrombin III from transgenic goat milk

Journal of Chemical Technology and Biotechnology

Volumn 86, Issue 10, 2011, Pages 1303-1309

  Kong, Yingjun ^a,b   Zhang, Guifeng ^a   Luo, Jian ^a   Liu, Yongdong ^a   Li, Xiunan ^a   Ma, Guanghui ^a   Zhao, Yalin ^c   Yuan, Sanping ^c   Su, Zhiguo ^a  

^a INSTITUTE OF PROCESS ENGINEERING   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c Qingdao Samuels Biotechnology Research Institute   (China)

Author keywords

Circular dichroism spectra; Fluorescence emission spectra; Heparin affinity chromatography; Human antithrombin III; Isoelectric point precipitation; Liquid chromatography mass spectrometry; Transgenic goat milk

Indexed keywords

CIRCULAR DICHROISM SPECTRA; FLUORESCENCE EMISSION SPECTRA; HEPARIN AFFINITY CHROMATOGRAPHY; HUMAN ANTITHROMBIN III; ISO-ELECTRIC POINTS; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; TRANSGENICS;

AFFINITY CHROMATOGRAPHY; AMINO ACIDS; COLUMN CHROMATOGRAPHY; DICHROISM; EMISSION SPECTROSCOPY; INDUSTRIAL EMISSIONS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; ORGANIC POLYMERS; PLANTS (BOTANY); POLYSACCHARIDES; PROTEINS; PURIFICATION;

SIZE EXCLUSION CHROMATOGRAPHY;

BETA CASEIN; ENTEROPEPTIDASE; RECOMBINANT ANTITHROMBIN III;

AFFINITY CHROMATOGRAPHY; AMINO ACID SEQUENCE; ARTICLE; DISULFIDE BOND; GEL PERMEATION CHROMATOGRAPHY; GLYCOSYLATION; MILK; PRECIPITATION; PROTEIN PURIFICATION; PROTEIN SECONDARY STRUCTURE; TRANSGENIC GOAT;

ANIMALIA; CAPRA HIRCUS;

EID: 80052967691     PISSN: 02682575     EISSN: 10974660     Source Type: Journal    
DOI: 10.1002/jctb.2673     Document Type: Article

References (27)

1. Niemann H and Kues W, Transgenic farm animals: an update. Reprod Fertil Dev 19: 762-770 (2007).
2. Goldman I, Kadulin S and Razin S, Transgenic goats in the world pharmaceutical industry of the 21st century. Russ J Genet 38: 1-14 (2002).
3. Rosenberg RD, Bauer KA and Marcum JA, Antithrombin-III-the heparin-antithrombin system. J Med 16: 351-416 (1985).
4. Murano G, Williams L, Miller-Andersson M, Aronson D and King C, Some properties of antithrombin-III and its concentration in human plasma. Thromb Res 18: 259-262 (1980).
5. Saigo M, Abe S, Ogawa M, Yamashita T, Biro S, Minagoe S, et al, Imbalance of plasminogen activator inhibitor-I/tissue plasminogen activator and tissue factor/tissue factor pathway inhibitor in young Japanese men with myocardial infarction. Thromb Haemostasis 86: 1197-1203 (2001).
6. Schuster H, AT III in septicemia with DIC. Intensive Care Med 19: 16-18 (1993).
7. Eisele B, Heinrichs H, Delvos U, Lamy M, Thijs L, Keinecke H, et al, Antithrombin III in patients with severe sepsis. Intensive Care Med 24: 663-672 (1998).
8. Fourrier F, Therapeutic applications of antithrombin concentrates in systemic inflammatory disorders. Blood Coagul Fibrinolysis 9: S39-S45 (1998).
9. Smith J, Winkelman L and Evans D, A pasteurized AT-III concentrate for clinical use. Vox Sang 48: 325-332 (1985).
10. Hoffman D, Purification and large-scale preparation of antithrombin III. Am J Med 87: S23-S26 (1989).
11. Lebing W, Hammond D, Wydick III J and Baumbach G, A highly purified antithrombin III concentrate prepared from human plasma fraction IV-1 by AC. Vox Sang 67: 117-124 (1994).
12. Zettlmeissl G, Conradt H, Nimtz M and Karges H, Characterization of recombinant human antithrombin III synthesized in Chinese hamster ovary cells. J Biol Chem 264: 21153-21159 (1989).
13. Edmunds T, Van Patten SM, Pollock J, Hanson E, Bernasconi R, Higgins E, et al, Transgenically produced human antithrombin: structural and functional comparison to human plasma-derived antithrombin. Blood 91: 4561-4571 (1998).
14. Echelard Y, Ziomek CA and Meade HM, Production of recombinant therapeutic proteins in the milk of transgenic animals. Biopharm Int 19: 36-45 (2006).
15. Wilmut I, Schnieke AE, McWhir J, Kind AJ and Campbell KHS, Viable offspring derived from fetal and adult mammalian cells. Nature 385: 810-813 (1997).
16. Zou X, Yuan S, Xian J, Zhao Y, Li D, Wang Y, et al, Large scale production of recombinant hum an antithrombin III(rhATIII)in transgenic cloned goats. Chinese J Biotechnol 24: 117-123 (2008).
17. Kaetzel C and Ray D, Immunochemical characterization with monoclonal antibodies of three major caseins and alpha-lactalbumin from rat milk. J Dairy Sci 67: 64-75 (1984).
18. Morcol T and Bell S, Method for Processing Milk. US Patents US6183803 (1999).
19. Blomback M, Blomback B, Olsson P and Svendsen L, The assay of antithrombin using a synthetic chromogenic substrate for thrombin. Thromb Res 5: 621-632 (1974).
20. Laemmli U, Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685 (1970).
21. Holt C, Casein micelle substructure and calcium phosphate interactions studied by sephacryl column chromatography. J Dairy Sci 81: 2994-3003 (1998).
22. Wickerhauser M, Williams C and Mercer J, Development of large scale fractionation methods. VII. Preparation of antithrombin III concentrate. Vox Sang 36: 281-293 (1979).
23. Gasteiger E, Hoogland C, Gattiker A, Duvaud S, Wilkins M, Appel R, et al, Protein identification and analysis tools on the ExPASy server. in The Proteomics Protocols Handbook, ed by John MW. Humuna Press Inc, 571-607 (2005).
24. Wishart D, Fortin S, Woloschuk D, Wong W, Rosborough T, Van Domselaar G, et al, A platform-independent graphical user interface for SEQSEE and XALIGN. Bioinformatics 13: 561 (1997).
25. Ersdal-Badju E, Lu A, Zuo Y, Picard V and Bock S, Identification of the antithrombin III heparin binding site. J Biol Chem 272: 19393-19400 (1997).
26. Carrell R, Stein P, Fermi G and Wardell M, Biological implications of a 3 structure of dimeric antithrombin. Structure 2: 257-270 (1994).
27. Franzen L, Svensson S and Larm O, Structural studies on the carbohydrate portion of human antithrombin III. J Biol Chem 255: 5090-5093 (1980).